Clinicopathological features of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation

Table 1 Clinicopathological findings for patients with gastric cancer with enteroblastic differentiation

Case	1	2	3	4	5	6
Age, yr	61	77	78	75	80	83
Male/female	Male	Male	Male	Male	Female	Male
Tumor location: U/M/L	L	M	U	U	L	M
Tumor size, mm	8	11	14	18	6	36
Macroscopic type	0-IIc	0-IIc	0-IIc	0-IIa	0-IIc	0-IIa + I
H. pylori infection	HPIgG+	HPIgG+	HPIgG-	NA	HPIgG+	HPIgG+
Procedure method	ESD	ESD	ESD with additional surgery	ESD	ESD	ESD with additional surgery
Depth of invasion (μm)	M	SM (1500)	SM (1000)	SM (200)	M	SM (2000)
Lymphatic invasion	(-)	(-)	(-)	(-)	(+)	(+)
Venous invasion	(-)	(+)	(+)	(+)	(-)	(+)
Observation period (mo)	51, ANED	42, ANED	N/A	38, ANED	N/A	28, ANED
Immunohistochemical analysis
AFP	(+)	(-)	(-)	(-)	(-)	(-)
Glypican3	(+)	(+)	(+)	(+)	(-)	(+)
SALL4	(+)	(-)	(-)	(-)	(+)	(-)
MUC2	(-)	(-)	(-)	(+)	(-)	(-)
MUC5AC	(-)	(-)	(-)	(+)	(-)	(-)
MUC6	(-)	(+)	(+)	(+)	(-)	(+)
CD10	(+)	(+)	(+)	(+)	(+)	(+)
P53	(-)	(-)	(+)	(+)	(+)	(-)

U: Upper third of stomach; M: Middle third of stomach; L: Lower third of stomach; H. pylori: Helicobacter pylori; IgG: Immunoglobulin G; ESD: Endoscopic submucosal dissection; M: Mucosa; SM: Submucosa; ANED: Alive with no evidence of disease; N/A: Not applicable; AFP: Alpha-fetoprotein.